Stocks
Nektar TherapeuticsNKTR
NASDAQHealthcareBiotechnology$73.25+4.11%
Focused on developing innovative immunology and oncology therapies, this biopharmaceutical company is known for its research into cytokine-based treatments. Investors monitor its pipeline progress and partnerships with larger pharmaceutical firms.
Market Cap: $1.5B52W Range: $6.45 – $77.00
Congressional Interest in Nektar Therapeutics (NKTR)
3 members of Congress have disclosed 18 trades in Nektar Therapeutics (NKTR), a Healthcare company. The buy/sell breakdown shows 13 purchases versus 4 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
18
Unique Politicians
3
Buys
13
Sells
4
Who in Congress Is Trading NKTR?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2019-12-24 | MICHAEL T. MCCAUL | exchange | $1K – $15K |
| 2019-01-10 | MICHAEL T. MCCAUL | buy | $1K – $15K |